PMD42 Cost-Effectiveness of Using the UGT1A1 Pharmacogenetic Test to Reduce the Incidence of Irinotecan Chemotherapy-related Febrile Neutropaenia
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.114
https://www.valueinhealthjournal.com/article/S1098-3015(11)01676-7/fulltext
Title :
PMD42 Cost-Effectiveness of Using the UGT1A1 Pharmacogenetic Test to Reduce the Incidence of Irinotecan Chemotherapy-related Febrile Neutropaenia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01676-7&doi=10.1016/j.jval.2011.08.114
First page :
A251
Section Title :
Medical Device/Diagnostics
Open access? :
No
Section Order :
94